Asia Pacific Biopharmaceutical Contract Manufacturing Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Biologics and Biosimilar), Source (Microbial and Mammalian), Application (Commercial and Clinical), and Therapeutic Area (Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and Others)
The Asia Pacific Biopharmaceutical Contract Manufacturing Market is poised for remarkable growth, projected to reach approximately US$ 26,544.2 million by 2031, up from US$ 10,448.9 million in 2024. This growth trajectory indicates a compound annual growth rate (CAGR) of 14.3% from 2025 to 2031, highlighting the region's increasing significance in the global biopharmaceutical landscape.
Executive Summary
The biopharmaceutical contract manufacturing sector in the Asia Pacific, which includes key markets such as China, Japan, India, Australia, and South Korea, is set to expand significantly. Countries like Australia, India, and South Korea are emerging as pivotal players, driven by advancements in healthcare infrastructure, increased investments in research and development, and supportive government policies that facilitate clinical trials. Governments in the region are enhancing regulatory frameworks and providing incentives to attract global biopharmaceutical companies to conduct trials and establish manufacturing operations locally.
The rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, is fueling the demand for new biologics and biosimilars, thereby creating fresh opportunities for contract manufacturers. The region's cost advantages, skilled workforce, and the adoption of modern manufacturing technologies further enhance its appeal, positioning Asia Pacific as a key hub for biopharmaceutical contract manufacturing in the coming years.
Market Segmentation Analysis
The Asia Pacific Biopharmaceutical Contract Manufacturing Market can be segmented based on product type, source, application, and therapeutic area:
The rise of personalized medicine presents a significant opportunity within the biopharmaceutical contract manufacturing market. Personalized medicine focuses on tailored treatments that align with the unique genetic profiles, environments, and lifestyles of individual patients. The increasing adoption of personalized medicine is driven by advancements in genomics, biotechnology, and diagnostics, which enable more precise and effective treatments. This trend is creating a demand for specialized, flexible, and scalable manufacturing solutions.
As biopharmaceutical companies seek to bring personalized therapies to market, they are increasingly collaborating with contract manufacturing organizations (CMOs) that possess the expertise and capacity to handle these specialized manufacturing needs. Personalized therapies often require tailored manufacturing processes, including gene therapies, cell therapies, and precision oncology treatments. For instance, in June 2024, Aragen Life Sciences announced a $30 million investment to establish a biologics manufacturing facility in Bangalore, India, aimed at supporting the development of complex therapies, including small-batch, high-complexity biologics crucial for personalized treatment. This initiative directly addresses the growing demand for customized, patient-specific medicines.
The increasing focus on personalized medicine underscores the necessity for efficient and scalable manufacturing processes capable of adapting to the production of highly individualized treatments. CMOs that can provide specialized services for producing cell-based therapies or gene-editing technologies, such as CRISPR-based treatments, are well-positioned to capitalize on this trend. As companies shift towards smaller batch sizes and greater customization, CMOs play a vital role in ensuring that these innovative treatments are produced efficiently and cost-effectively, thereby creating lucrative opportunities in the market during the forecast period.
Country Insights
The Asia Pacific Biopharmaceutical Contract Manufacturing Market is further segmented by country, including China, Japan, India, Australia, South Korea, and the Rest of APAC. China is expected to hold the largest market share in 2024, driven by favorable regulatory reforms and strategic industry expansions in the biopharmaceutical contract manufacturing sector. The National Medical Products Administration (NMPA) in China has initiated a pilot program that allows for segmented production of biological products, enabling biopharma companies to outsource various production stages to contract development and manufacturing organizations (CDMOs). This regulatory advancement enhances production flexibility, reduces operational costs, and improves time-to-market efficiency.
Leading CDMOs, such as Boehringer Ingelheim BioXcellence, are expanding their service offerings in China, introducing tailored service packages to meet diverse biopharmaceutical production needs. These enhancements enable both local and multinational biopharma firms to navigate complex regulatory and manufacturing requirements, thereby strengthening the sustainable global supply of critical medications. The combination of regulatory advancements and industry investment fosters a robust environment for CDMO growth in China's biopharmaceutical sector.
Conclusion
The Asia Pacific Biopharmaceutical Contract Manufacturing Market is on a robust growth path, driven by increasing demand for biologics, biosimilars, and personalized medicine. With strategic investments and regulatory support, the region is set to become a central hub for biopharmaceutical manufacturing, offering significant opportunities for contract manufacturers and biopharmaceutical companies alike.
Executive Summary
The biopharmaceutical contract manufacturing sector in the Asia Pacific, which includes key markets such as China, Japan, India, Australia, and South Korea, is set to expand significantly. Countries like Australia, India, and South Korea are emerging as pivotal players, driven by advancements in healthcare infrastructure, increased investments in research and development, and supportive government policies that facilitate clinical trials. Governments in the region are enhancing regulatory frameworks and providing incentives to attract global biopharmaceutical companies to conduct trials and establish manufacturing operations locally.
The rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, is fueling the demand for new biologics and biosimilars, thereby creating fresh opportunities for contract manufacturers. The region's cost advantages, skilled workforce, and the adoption of modern manufacturing technologies further enhance its appeal, positioning Asia Pacific as a key hub for biopharmaceutical contract manufacturing in the coming years.
Market Segmentation Analysis
The Asia Pacific Biopharmaceutical Contract Manufacturing Market can be segmented based on product type, source, application, and therapeutic area:
- By Product Type: The market is divided into Biologics and Biosimilars, with Biologics holding the largest market share in 2024.
- By Source: The segmentation includes Microbial and Mammalian sources, where Microbial is expected to dominate the market in 2024.
- By Application: The market is categorized into Commercial and Clinical applications, with Commercial applications leading in market share in 2024.
- By Therapeutic Area: This includes Oncology, Autoimmune Disorders, Respiratory Disorders, Metabolic Disorders, Neurology, Infectious Diseases, and others, with Oncology being the largest segment in 2024.
The rise of personalized medicine presents a significant opportunity within the biopharmaceutical contract manufacturing market. Personalized medicine focuses on tailored treatments that align with the unique genetic profiles, environments, and lifestyles of individual patients. The increasing adoption of personalized medicine is driven by advancements in genomics, biotechnology, and diagnostics, which enable more precise and effective treatments. This trend is creating a demand for specialized, flexible, and scalable manufacturing solutions.
As biopharmaceutical companies seek to bring personalized therapies to market, they are increasingly collaborating with contract manufacturing organizations (CMOs) that possess the expertise and capacity to handle these specialized manufacturing needs. Personalized therapies often require tailored manufacturing processes, including gene therapies, cell therapies, and precision oncology treatments. For instance, in June 2024, Aragen Life Sciences announced a $30 million investment to establish a biologics manufacturing facility in Bangalore, India, aimed at supporting the development of complex therapies, including small-batch, high-complexity biologics crucial for personalized treatment. This initiative directly addresses the growing demand for customized, patient-specific medicines.
The increasing focus on personalized medicine underscores the necessity for efficient and scalable manufacturing processes capable of adapting to the production of highly individualized treatments. CMOs that can provide specialized services for producing cell-based therapies or gene-editing technologies, such as CRISPR-based treatments, are well-positioned to capitalize on this trend. As companies shift towards smaller batch sizes and greater customization, CMOs play a vital role in ensuring that these innovative treatments are produced efficiently and cost-effectively, thereby creating lucrative opportunities in the market during the forecast period.
Country Insights
The Asia Pacific Biopharmaceutical Contract Manufacturing Market is further segmented by country, including China, Japan, India, Australia, South Korea, and the Rest of APAC. China is expected to hold the largest market share in 2024, driven by favorable regulatory reforms and strategic industry expansions in the biopharmaceutical contract manufacturing sector. The National Medical Products Administration (NMPA) in China has initiated a pilot program that allows for segmented production of biological products, enabling biopharma companies to outsource various production stages to contract development and manufacturing organizations (CDMOs). This regulatory advancement enhances production flexibility, reduces operational costs, and improves time-to-market efficiency.
Leading CDMOs, such as Boehringer Ingelheim BioXcellence, are expanding their service offerings in China, introducing tailored service packages to meet diverse biopharmaceutical production needs. These enhancements enable both local and multinational biopharma firms to navigate complex regulatory and manufacturing requirements, thereby strengthening the sustainable global supply of critical medications. The combination of regulatory advancements and industry investment fosters a robust environment for CDMO growth in China's biopharmaceutical sector.
Conclusion
The Asia Pacific Biopharmaceutical Contract Manufacturing Market is on a robust growth path, driven by increasing demand for biologics, biosimilars, and personalized medicine. With strategic investments and regulatory support, the region is set to become a central hub for biopharmaceutical manufacturing, offering significant opportunities for contract manufacturers and biopharmaceutical companies alike.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET LANDSCAPE
4.1 PEST Analysis
5. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - ASIA PACIFIC MARKET ANALYSIS
6.1 Asia Pacific Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
6.2 Asia Pacific Biopharmaceutical Contract Manufacturing Market Forecast and Analysis
7. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Biosimilar
7.2.1 Overview
7.2.2 Biosimilar: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY SOURCE
8.1 Microbial
8.1.1 Overview
8.1.2 Microbial: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Mammalian
8.2.1 Overview
8.2.2 Mammalian: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Commercial
9.1.1 Overview
9.1.2 Commercial: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Clinical
9.2.1 Overview
9.2.2 Clinical: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
10.1 Oncology
10.1.1 Overview
10.1.2 Oncology: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Autoimmune Disorders
10.2.1 Overview
10.2.2 Autoimmune Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Respiratory Disorders
10.3.1 Overview
10.3.2 Respiratory Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4 Metabolic Disorders
10.4.1 Overview
10.4.2 Metabolic Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5 Neurology
10.5.1 Overview
10.5.2 Neurology: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6 Infectious Diseases
10.6.1 Overview
10.6.2 Infectious Diseases: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - COUNTRY ANALYSIS
11.1 Asia Pacific
11.1.1 Asia Pacific Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.1.1 Asia Pacific Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.2.2 China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 China: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.1.2.2.2 China: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.1.2.2.3 China: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.1.2.2.4 China: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.2.3.3 Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.2.3.3.2 Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.2.3.3.3 Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.2.3.3.4 Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.3.4.4 India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 India: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.3.4.4.2 India: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.3.4.4.3 India: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.3.4.4.4 India: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.4.5.5 Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4.5.5.1 Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.4.5.5.2 Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.4.5.5.3 Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.4.5.5.4 Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.5.6.6 South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.5.6.6.1 South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.5.6.6.2 South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.5.6.6.3 South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.5.6.6.4 South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.6.7.7 Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.6.7.7.1 Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.6.7.7.2 Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.6.7.7.3 Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.6.7.7.4 Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Boehringer Ingelheim International GmbH
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Lonza Group AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 AbbVie Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Samsung Biologics Co Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 WuXi Biologics Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Ajinomoto Co Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Cytiva
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AGC Biologics AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET LANDSCAPE
4.1 PEST Analysis
5. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - ASIA PACIFIC MARKET ANALYSIS
6.1 Asia Pacific Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
6.2 Asia Pacific Biopharmaceutical Contract Manufacturing Market Forecast and Analysis
7. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Biosimilar
7.2.1 Overview
7.2.2 Biosimilar: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY SOURCE
8.1 Microbial
8.1.1 Overview
8.1.2 Microbial: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Mammalian
8.2.1 Overview
8.2.2 Mammalian: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Commercial
9.1.1 Overview
9.1.2 Commercial: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Clinical
9.2.1 Overview
9.2.2 Clinical: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
10.1 Oncology
10.1.1 Overview
10.1.2 Oncology: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Autoimmune Disorders
10.2.1 Overview
10.2.2 Autoimmune Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Respiratory Disorders
10.3.1 Overview
10.3.2 Respiratory Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4 Metabolic Disorders
10.4.1 Overview
10.4.2 Metabolic Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5 Neurology
10.5.1 Overview
10.5.2 Neurology: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6 Infectious Diseases
10.6.1 Overview
10.6.2 Infectious Diseases: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. ASIA PACIFIC BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET - COUNTRY ANALYSIS
11.1 Asia Pacific
11.1.1 Asia Pacific Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.1.1 Asia Pacific Biopharmaceutical Contract Manufacturing Market Revenue and Forecast and Analysis - by Country
11.1.2.2 China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 China: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.1.2.2.2 China: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.1.2.2.3 China: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.1.2.2.4 China: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.2.3.3 Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.2.3.3.2 Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.2.3.3.3 Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.2.3.3.4 Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.3.4.4 India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 India: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.3.4.4.2 India: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.3.4.4.3 India: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.3.4.4.4 India: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.4.5.5 Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4.5.5.1 Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.4.5.5.2 Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.4.5.5.3 Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.4.5.5.4 Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.5.6.6 South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.5.6.6.1 South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.5.6.6.2 South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.5.6.6.3 South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.5.6.6.4 South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
11.6.7.7 Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.6.7.7.1 Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Product Type
11.6.7.7.2 Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Source
11.6.7.7.3 Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Application
11.6.7.7.4 Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market Share - by Therapeutic Area
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Boehringer Ingelheim International GmbH
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Lonza Group AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 AbbVie Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Samsung Biologics Co Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 WuXi Biologics Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Ajinomoto Co Inc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Cytiva
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AGC Biologics AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
LIST OF TABLES
Table 1. Asia Pacific Biopharmaceutical Contract Manufacturing Market Segmentation
Table 3. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 6. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 8. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 11. China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 12. China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 13. Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 14. Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 15. Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 17. India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 19. India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 21. Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 22. Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 23. Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 25. South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 26. South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 27. South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 28. South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 29. Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 30. Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 31. Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 32. Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 33. Heat Map Analysis by Key Players
Table 1. Asia Pacific Biopharmaceutical Contract Manufacturing Market Segmentation
Table 3. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 6. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 8. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 11. China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 12. China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 13. Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 14. Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 15. Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 16. Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 17. India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 18. India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 19. India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 20. India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 21. Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 22. Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 23. Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 25. South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 26. South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 27. South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 28. South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 29. Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 30. Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
Table 31. Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 32. Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Therapeutic Area
Table 33. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Asia Pacific Biopharmaceutical Contract Manufacturing Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Asia Pacific Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. Asia Pacific Biopharmaceutical Contract Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Biologics: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Biosimilar: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Asia Pacific Biopharmaceutical Contract Manufacturing Market Share (%) - by Source, 2024 and 2031
Figure 11. Microbial: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Mammalian: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Asia Pacific Biopharmaceutical Contract Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 14. Commercial: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Clinical: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Asia Pacific Biopharmaceutical Contract Manufacturing Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 17. Oncology: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Autoimmune Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Respiratory Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Metabolic Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Neurology: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Infectious Diseases: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Others: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Asia Pacific Biopharmaceutical Contract Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Company Positioning & Concentration
Figure 1. Asia Pacific Biopharmaceutical Contract Manufacturing Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. Asia Pacific Biopharmaceutical Contract Manufacturing Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Asia Pacific Biopharmaceutical Contract Manufacturing Market Revenue (US$ Million), 2024 - 2031
Figure 7. Asia Pacific Biopharmaceutical Contract Manufacturing Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Biologics: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Biosimilar: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Asia Pacific Biopharmaceutical Contract Manufacturing Market Share (%) - by Source, 2024 and 2031
Figure 11. Microbial: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Mammalian: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Asia Pacific Biopharmaceutical Contract Manufacturing Market Share (%) - by Application, 2024 and 2031
Figure 14. Commercial: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Clinical: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Asia Pacific Biopharmaceutical Contract Manufacturing Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 17. Oncology: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Autoimmune Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Respiratory Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Metabolic Disorders: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Neurology: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Infectious Diseases: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Others: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Asia Pacific Biopharmaceutical Contract Manufacturing Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. China: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Japan: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. India: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Australia: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. South Korea: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Rest of APAC: Asia Pacific Biopharmaceutical Contract Manufacturing Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Company Positioning & Concentration
